Compare Abeona Therapeutics Inc (ABEO) vs Modine Manufacturing Company (MOD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Modine Manufacturing Company — how do they compare? Abeona Therapeutics Inc trades at $6.7 (market cap $373.32M), while Modine Manufacturing Company trades at $223.89 (market cap $12.17B). The key difference: Modine Manufacturing Company is far larger — about 32.6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Modine Manufacturing Company nearer its low. Which is the better fit depends on your goals.
| ABEO | MOD | |
|---|---|---|
Market Cap | $373.32M | $12.17B |
Sector | Health | Technology |
52-Week High | $7.23 | $306.89 |
52-Week Low | $4.17 | $90.02 |
Enterprise Value | $228.22M | $12.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Modine (MOD) trades at $235.19, up 1.83% on the day, amid a bearish technical signal despite recent earnings beats. The company reported strong revenue growth to $2.58B in 2025, with net income of $184M, though 2026 projections show margin compression. Analyst consensus remains strongly bullish with a $328.80 price target, driven by optimism around its data center cooling business, which is expected to grow 60-80% in FY27 according to Seeking Alpha (2026-06-11).
The outlook is mixed: robust growth in data center demand offers significant upside, but high valuations (P/E 104.07) and near-term technical weakness pose risks. Investors face volatility from supply chain challenges and competitive pressures in the HVAC segment, though institutional support and consistent earnings outperformance provide a foundation for long-term growth if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →
